Abstract
Rotavirus virus-like particles (RV-VLPs) represent a novel strategy for development of a rotavirus subunit vaccine. In this study, RF 8-2/6/7-VLPs with rotavirus VP8 protein (amino acid 1-241 of VP4) fused to the amino terminal end of a truncated VP2, were evaluated for their immunogenic and protective properties. A single intramuscular dose of, either 2 or 20 microg, RF 8-2/6/7-VLPs alone or combined with a potent adjuvant poly[di(carboxylatophenoxy)]phosphazene] (PCPP) induced rotavirus-specific serum IgG and IgA, fecal IgG titers that were enhanced 5-90-fold by adjuvant. Passive protective immunity was achieved in offspring to dams vaccinated with 2 and 20 microg RV-VLPs in presence of adjuvant and 20 microg RV-VLP without adjuvant.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Animals
-
Antibodies, Viral / blood
-
Feces / chemistry
-
Female
-
Immunoglobulin A / blood
-
Immunoglobulin G / analysis
-
Immunoglobulin G / blood
-
Injections, Intramuscular
-
Mice
-
Mice, Inbred BALB C
-
Microscopy, Electron, Transmission
-
Organophosphorus Compounds / administration & dosage
-
Organophosphorus Compounds / immunology
-
Polymers / administration & dosage
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
Rotavirus / immunology*
-
Rotavirus Infections / prevention & control*
-
Vaccines, Virosome / administration & dosage
-
Vaccines, Virosome / immunology
-
Viral Proteins / genetics
-
Viral Proteins / immunology
-
Virosomes / ultrastructure
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Ca-poly(bis(carboxylatophenoxy)phosphazene)
-
Immunoglobulin A
-
Immunoglobulin G
-
Organophosphorus Compounds
-
Polymers
-
Recombinant Fusion Proteins
-
Vaccines, Virosome
-
Viral Proteins
-
Virosomes